Thymulin

01 · What it is

Almost every human finding about thymulin is a finding about zinc.

Thymulin is a nonapeptide hormone produced by thymic epithelial cells, formerly called FTS ³. It consists of a nonapeptide coupled to a zinc ion, and it is the zinc that confers biological activity on the molecule ¹². Without its metal, the peptide is inert. That single fact governs everything else in this guide, including what any material sold under this name would need to be.

The human literature measures thymulin; it does not administer it. The largest body of human data comes from experimental zinc-deficiency work: mild zinc deficiency in humans decreases serum thymulin activity ^10,13,17, and the effect is corrected by zinc given in vivo and in vitro ⁶. In elderly patients, zinc supplementation corrected zinc deficiency and raised serum thymulin activity, interleukin-1 production and lymphocyte ecto-5′-nucleotidase, with improved skin-test responses ⁵.

Read that last sentence carefully. The intervention was zinc. Thymulin was an outcome measure.

This guide located no clinical trial in which thymulin itself was administered to people. The compound dates to French endocrinology of the 1970s ¹, and trials of that era may exist outside the indexing used here — but none surfaced, and the honest statement is that they were not found rather than that they do not exist.

What does exist is a coherent animal and mechanistic literature. Thymulin has documented anti-inflammatory properties across several animal models of lung disease ¹⁵, has been reviewed alongside thymosin-alpha and thymopoietin as a prospective anti-inflammatory agent ¹⁶, acts on the neuroendocrine system ¹², and circulates to affect immune and other cells in the periphery ¹⁸.

Thymulin is a well-characterised endogenous hormone, a validated biomarker of zinc status, and — on the evidence located here — an untested therapeutic.

02 · Evidence at a glance

Evidence grade

Preclinical — no trial of administered thymulin located

What it is

A nonapeptide produced by thymic epithelial cells, formerly FTS ³

Critical structural fact

Biologically active only when coupled to zinc ¹²

Zinc dependence, demonstrated

Serum thymulin activity falls in zinc deficiency and is restored by zinc ^6,10,13

Human intervention studies of thymulin itself

None located

Human studies where thymulin is the outcome

Several — zinc deficiency and supplementation ^5,10,13,17

Best human dataset

Experimental human zinc deficiency ¹⁷ and zinc supplementation in elderly patients ⁵

What that dataset tests

Zinc, not thymulin

Animal evidence

Anti-inflammatory effects across models of lung disease ¹⁵; neuroendocrine actions ¹²

Role in the thymic-hormone family

One of three classical thymic hormones with thymosin alpha-1 and thymopoietin ^4,16,18

Published human toxicology

None located

Approval status

None identified in any jurisdiction

US regulatory status

Not an approved drug; not a lawful dietary supplement ingredient

03 · Mechanism of action

The zinc is not an accessory

Thymulin consists of a nonapeptide component coupled to the ion zinc, which confers biological activity to the molecule ¹². The thymus is described as packaging zinc into zinc-thymulin for delivery to the periphery ⁸ — a framing in which the peptide is partly a carrier and the metal is part of the active principle.

This is the most consequential sentence in the guide. A nonapeptide supplied without zinc is not a weaker version of thymulin; on the account given in this literature it is a different and inactive thing. No paper cited here reports what proportion of any preparation is present as the zinc-bound form.

What it acts on

Thymulin acts preferentially on T-cell subsets rather than uniformly across them ¹, with the effect on suppressor T-cells identified early as the most notable ³. It is required for the maturation of T-helper cells, which is why its activity falls measurably when zinc is deficient ¹³. Like other thymic hormones it circulates and acts on both prothymocytes and mature peripheral T-cells, maintaining their commitment to the T-cell lineage ⁴.

Beyond immunity, thymulin has documented interactions with the neuroendocrine system ¹² and anti-inflammatory activity in its own right ^15,16.

The zinc-status feedback loop is the best-evidenced thing about it

Zinc deficiency in humans decreases serum thymulin activity ^13,17; zinc repletion restores it ^5,6. In experimental mild human zinc deficiency, decreased thymulin activity in Th1 cells appears alongside decreased IL-2 and IFN-γ messenger RNA ¹⁷. Thymulin’s relevance in resistance to viral, fungal and bacterial infection is described specifically through zinc’s role in conferring biological activity on it ¹¹.

A hormone whose measured activity tracks a nutrient’s availability is an excellent assay for that nutrient. It is a much weaker basis for concluding that supplying the hormone would do anything useful in someone who is not deficient, and no study cited here tests that.

04 · Key research findings

The founding endocrinology, 1979. A review of thymic hormones noting that three had been chemically characterised, sequenced and synthesised — thymosin alpha-1, thymopoietin and the serum thymic factor — and that thymic hormones act preferentially rather than identically on T-cell subsets ¹.

Thymulin under its original name, placed in the family it belongs to, nearly fifty years ago.

Characterisation as a zinc-dependent hormone, 1989. A review defining thymulin as a well-defined nonapeptide produced by thymic epithelial cells and identifying its effect on suppressor T-cells as the most remarkable and the most likely to find clinical application ³.

The clinical application anticipated in 1989 has not arrived in the literature located for this guide.

Zinc supplementation in elderly patients, 1993. Zinc supplementation corrected zinc deficiency and normalised plasma copper. Serum thymulin activity, interleukin-1 production and lymphocyte ecto-5′-nucleotidase all increased significantly, with improved skin-test antigen responses ⁵.

A genuine human interventional result with clinical endpoints — and the intervention is a mineral available in any pharmacy. Thymulin is the mediator being measured, not the treatment being given.

The zinc–thymulin relationship, 1994. Serum thymulin activity decreased with zinc deficiency across models in experimental animals and in humans, and was corrected by zinc both in vivo and in vitro ⁶.

In vitro correction is the striking half: adding zinc to serum restores measurable activity, which is what one expects if the metal is part of the active molecule rather than a regulator of its production.

Zinc and immunity, 1988–2008. A sustained programme establishing that thymulin activity is among the immune parameters adversely affected by even mild zinc deficiency in humans ^{2,7,9,10,13,14}. Its recurring difficulty is diagnostic rather than therapeutic: recognising mild zinc deficiency in humans is hard, and plasma zinc is an imperfect measure of it ^2,7.

That difficulty is why thymulin activity became useful as an assay in the first place — it reads out functional zinc status better than plasma zinc does. It is a strong argument for thymulin as an instrument and no argument at all for thymulin as a treatment.

Experimental human zinc deficiency, 2020. A retrospective on that programme, reporting decreased thymulin activity in Th1 cells alongside decreased IL-2 and IFN-γ messenger RNA in a model of mild human zinc deficiency ¹⁷.

Decades of consistent human work, all of it using thymulin as an instrument.

Lung disease, 2010. A review of thymulin’s immunomodulatory role, describing a broad spectrum of anti-inflammatory effects across several animal models of lung disease and proposing it as a candidate where alternative approaches are needed ¹⁵.

The clearest statement in the file of thymulin as a potential therapeutic — and its evidence is animal models.

Thymic hormones as anti-inflammatory agents, 2010. A review of the anti-inflammatory potential of thymulin, thymosin-alpha and thymopoietin across clinical and experimental studies, reporting regulation of inflammatory pathways ¹⁶.

Thymus-derived hormonal control of cancer, 2023. A review placing thymulin with thymosin and thymopoietin as thymic hormones that circulate to affect immune cells and other peripheral cellular components ¹⁸.

The most recent framing, and it is a review of the field rather than new evidence for the compound.

05 · Evidence overview

06 · Safety profile

Human data. None from administration. Every human study located here measures endogenous thymulin or gives zinc ^5,6,10,13,17, so there is no exposure dataset to report.

Animal data. No dedicated toxicology study appears in the literature located. Anti-inflammatory effects are reported across animal models of lung disease without adverse findings being described in the reviews ^15,16, which is not the same as a safety assessment.

What is genuinely unknown. Essentially everything relevant to human administration: pharmacokinetics, dose-finding, repeat-dose toxicology, genotoxicity, carcinogenicity, reproductive toxicity. None of it exists in the material located for this guide.

Two gaps deserve naming. The first is the zinc question, which is a safety and identity question at once: since biological activity depends on zinc coordination ¹², any preparation raises the unanswered question of whether it is the active zinc-bound form, the inactive apo-peptide, or a mixture — and nothing published addresses this for any commercial material. The second is that thymulin’s characteristic action is on suppressor T-cell populations ³, meaning it modulates immune regulation rather than simply boosting it. What that does in a person with autoimmune disease, or on immunosuppressive therapy, is unstudied.

07 · US regulatory status

Current as of 6 September 2026. Thymulin is not an approved drug in the United States, is not a controlled substance, and is not a lawful dietary supplement ingredient. No marketing authorisation in any jurisdiction was identified for this guide.

Under the World Anti-Doping Code, thymulin does not appear as a named prohibited substance in the classes reviewed here. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The human evidence base belongs to a different intervention. Decades of consistent, replicated human work uses thymulin as an outcome measure in studies of zinc ^{5,6,7,9,10,13,14,17}. The one human interventional study with clinical endpoints cited here supplemented zinc, not thymulin ⁵. This is the fifth compound in this project whose apparent human evidence turns out to be evidence about something else.

1. No trial of administered thymulin was located. The compound is nearly fifty years old ¹ and its clinical promise was being anticipated in 1989 ³. Older or non-English trials may exist and were not found; this guide states the absence of located evidence, not the absence of evidence.

1. Activity depends on zinc, and no preparation has been characterised for it. The literature is explicit that the zinc ion confers biological activity ¹² and that adding zinc restores activity in vitro ⁶. Nothing published establishes the zinc-bound fraction of any material, which makes the identity of anything sold under this name an open question before efficacy is even reached.

1. Animal-to-human translation is entirely unattempted. The therapeutic case rests on animal models of lung disease ¹⁵ and on reviews of anti-inflammatory potential ¹⁶. Neither has been tested in a person.

1. The most recent primary literature is old. The substantive mechanistic and human work cited here spans roughly 1979 to 2008 ^{1,3,5,6,7,9,10,13,14}. What follows is largely review ^15,16,17,18. A field that stops generating primary data has usually stopped for a reason, and nothing here establishes what it was.

1. Research concentration around a single question. The human literature is dominated by one research programme on zinc deficiency ^{5,7,9,10,13,14,17}. Its consistency is a strength for the zinc–thymulin relationship and tells a reader nothing about thymulin as a treatment.

1. Publication bias cannot be assessed, and is particularly opaque for a compound whose development-era trials, if they existed, would predate trial registration entirely.

1. No toxicology exists. Not a caveat about quality — an absence.

1. Modulation of suppressor T-cells is not the same as immune enhancement ³, and the difference matters most in exactly the populations most likely to be interested. Unstudied.

1. This guide has read abstracts, not full texts, for every source cited.

1. Nothing is known about material sold under this name. No published analysis has examined the identity, purity, or zinc content of any thymulin-labelled product.

09 · References

1. Bach JF. Thymic hormones. J Immunopharmacol. 1979;1(3):277–310. Review.

   PMID 233313 ↗

2. Prasad AS. Zinc in growth and development and spectrum of human zinc deficiency. J Am Coll Nutr. 1988 Oct;7(5):377–384. Review.

   PMID 3053862 ↗

3. Bach JF, Dardenne M. Thymulin, a zinc-dependent hormone. Med Oncol Tumor Pharmacother. 1989;6(1):25–29. Review.

   PMID 2657247 ↗

4. Hadden JW. Thymic endocrinology. Int J Immunopharmacol. 1992 Apr;14(3):345–352. Review.

   PMID 1618588 ↗

5. Prasad AS, Fitzgerald JT, Hess JW, Kaplan J, Pelen F, Dardenne M. Zinc deficiency in elderly patients. Nutrition. 1993 May–Jun;9(3):218–224.

   PMID 8353362 ↗

6. Dardenne M, Pleau JM. Interactions between zinc and thymulin. Met Based Drugs. 1994;1(2–3):233–239.

   PMID 18476235 ↗

7. Prasad AS. Zinc: an overview. Nutrition. 1995 Jan–Feb;11(1 Suppl):93–99. Review.

   PMID 7749260 ↗

8. Hadden JW. Thymic endocrinology. Ann N Y Acad Sci. 1998 May 1;840:352–358. Review.

   PMID 9629262 ↗

9. Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998 Aug;68(2 Suppl):447S–463S. Review.

   PMID 9701160 ↗

10. Prasad AS. Zinc and immunity. Mol Cell Biochem. 1998 Nov;188(1–2):63–69. Review.

    PMID 9823012 ↗

11. Mocchegiani E, Muzzioli M. Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J Nutr. 2000 May;130(5S Suppl):1424S–1431S. Review.

    PMID 10801955 ↗

12. Goya RG, Brown OA, Pléau JM, Dardenne M. Thymulin and the neuroendocrine system. Peptides. 2004 Jan;25(1):139–142. Review.

    PMID 15003367 ↗

13. Prasad AS. Zinc: mechanisms of host defense. J Nutr. 2007 May;137(5):1345–1349. Review.

    PMID 17449604 ↗

14. Prasad AS. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol. 2008 May;43(5):370–377. Review.

    PMID 18054190 ↗

15. Santos M, Henriques-Coelho T, Leite-Moreira A. Immunomodulatory role of thymulin in lung diseases. Expert Opin Ther Targets. 2010 Feb;14(2):131–141. Review.

    PMID 20055713 ↗

16. Lunin SM, Novoselova EG. Thymus hormones as prospective anti-inflammatory agents. Expert Opin Ther Targets. 2010 Aug;14(8):775–786. Review.

    PMID 20536297 ↗

17. Prasad AS. Lessons learned from experimental human model of zinc deficiency. J Immunol Res. 2020 Jan 9;2020:9207279.

    PMID 32411807 ↗

18. Savino W, Lepletier A. Thymus-derived hormonal and cellular control of cancer. Front Endocrinol (Lausanne). 2023 Jul 17;14:1168186. Review.

    PMID 37529610 ↗